Table 11.

Antiplatelet Trialists’ Collaboration^* Events through 56-Week Visit

	Sham+ Focal/Grid/PRP Laser N† = 102	Ranibizumab+ Focal/Grid/PRP Laser N† = 116	Triamcinolone+ Focal/Grid/PRP Laser N† = 115
Non-fatal myocardial infarction, no. (%)	1 (1%)	3 (3%)	0
Non-fatal cerebrovascular accident – ischemic or hemorrhagic (or unknown), no. (%)	1 (1%)	3 (3%)	4 (3%)
Vascular death (from any potential vascular or unknown cause), no. (%)	2 (2%)	3 (3%)	0
Any APTC event, no. (%)	4 (4%)	8§ (7%)	4 (3%)
Participants with prior cardiovascular events||	N=19	N=37	N=30
Any APTC event, no. (%)	1 (5%)	3 (8%)	0
Participants without prior cardiovascular events	N=83	N=79	N=85
Any APTC event, no. (%)	3 (4%)	5 (6%)	4 (5%)

^*Antiplatelet Trialists’ Collaboration. BMJ. 1994 Jan 8;308(6921):81–106.

PRP=Panretinal photocoagulation; APTC= Antiplatelet Trialists’ Collaboration.

^† N = Number of Study Participants. Study participants with 2 study eyes are assigned to the non-sham group. Multiple events within a study participant are only counted once per event.

^§1event occurred between baseline and 4 week injections, 1 event occurred approximately 3 weeks after the 4- week injection, and other events from the remaining 6 study participants occurred over 4 weeks after the 4-week injection.

^||According to participant reported history.